Brooklyn ImmunoTherapeutics Inc. (BTX): Price and Financial Metrics
BTX Price/Volume Stats
| Current price | $7.13 | 52-week high | $8.31 |
| Prev. close | $7.08 | 52-week low | $5.10 |
| Day low | $7.05 | Volume | 536,945 |
| Day high | $7.15 | Avg. volume | 745,361 |
| 50-day MA | $7.00 | Dividend yield | N/A |
| 200-day MA | $7.25 | Market Cap | 419.43M |
BTX Stock Price Chart Interactive Chart >
Brooklyn ImmunoTherapeutics Inc. (BTX) Company Bio
Brooklyn ImmunoTherapeutics, Inc. is a clinical stage biopharmaceutical company that develops IRX-2, a novel hd-IL-2 based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. The company is headquartered in New York, NY.
BTX Price Returns
| 1-mo | 0.56% |
| 3-mo | 24.76% |
| 6-mo | -2.31% |
| 1-year | 8.29% |
| 3-year | 24.50% |
| 5-year | 186.66% |
| YTD | 3.07% |
| 2024 | 13.41% |
| 2023 | 19.30% |
| 2022 | -47.76% |
| 2021 | 237.28% |
| 2020 | 1.82% |
Loading social stream, please wait...